EnBiotix is a product-focused inhaled antibiotics company advancing a late-stage pipeline aimed at front-line labeling for chronic, recurrent, and life-threatening pulmonary infections. Based upon the ground-breaking systems and synthetic biology of co-founder and SAB Chair Professor James J. Collins (MIT, Harvard Wyss, Broad) EnBiotix also expects to deliver a range of next-gen inhaled antibiotics in what is today a $15 billion market. As such, EnBiotix anticipates impacting the lives of patients, caregivers and payors worldwide.
This site is currently being updated to allow us to share announcements about exciting new strategic partnerships. Please check back soon for more information.